ACT 2023 -- Safety assessment of pharmaceuticals and chemicals with potential for repeated human exposure involves determining toxicity in studies that align with country-specific regulatory frameworks.
Liquid biopsies represent a transformation in the management of cancer as they have the potential to detect, characterize, and monitor cancers earlier than conventional diagnostic modalities.
The future is plasma. There is a growing body of evidence that demonstrates how incorporating liquid biopsy-based testing into cancer clinical trials can augment traditional tissue-based testing workflows and findings.
As an emerging biotech company developing antibody based therapeutics for oncology and non-oncology indications, Transcenta needed a full suite of studies for its investigational new drug (IND) package on Osemitamab (TST001), an antibody targeting a protein overexpressed in solid tumors.
DIA 2014 - Over the past five years a global cross-functional group (including clinical study teams, functional leaders and expert working groups) has collaborated to define and implement an enterprise RBM process.
